Bristol Myers Squibb 4Q Revenues: $11.5 billion (+1%)  4Q Earnings: $1.8 billion (-13%) FY Revenues: $45.0 billion (-2%)  FY Earnings: $8.0 billion (+27%) Comments: Higher sales of new product portfolio, as well as Eliquis and Opdivo sales, were partially offset by lower sales of Revlimid, down 38% to $1.5 billion. Total In-Line Products were up 5% to $8.7 billion. Eliquis sales were $2.9 billion in the quarter, up 7%. Opdivo sales were $2.4 billion, up 8%. Orencia sales were $985 million, ...